CinCor Pharma, Inc. (CINC)
After hours:
| Previous close | 29.04 |
| Open | 28.94 |
| Bid | 28.80 x 800 |
| Ask | 29.95 x 800 |
| Day's range | 28.94 - 29.16 |
| 52-week range | 10.53 - 43.15 |
| Volume | |
| Avg. volume | 600,316 |
| Market cap | 1.276B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.40 |
| Earnings date | 03 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 39.00 |
- Motley Fool
Why These Two Biotech Stocks Blasted Higher This Week
Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca, while Albireo Pharma (NASDAQ: ALBO) is set to be owned by France-based peer Ipsen. Both of these deals are very lucrative, to the point where CinCor's stock rocketed 146% over the course of the week, and Albireo shot 92% skyward, according to data compiled by S&P Global Market Intelligence.
- Zacks
Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More
Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.
- Zacks
AstraZeneca (AZN) Set to Acquire CinCor Pharma for $1.3B
AstraZeneca's (AZN) CinCor Pharma buyout is going to add blood pressure drug baxdrostat to its cardiorenal pipeline.
